Oncogematologiya最新文献

{"title":"Clinical possibilities of flow cytometry in hodgkin’s lymphoma","authors":"F. M. Abbasbeyli, A. A. Fedenko, P. A. Zeynalova, R. F. Zibirov, V. N. Grinevich, T. Yu. Mushkarina, A. A. Melnikova, M. A. Vernyuk, L. Yu. Grivtsova","doi":"10.17650/1818-8346-2023-18-3-70-77","DOIUrl":"https://doi.org/10.17650/1818-8346-2023-18-3-70-77","url":null,"abstract":"Hodgkin’s lymphoma (HL) is a unique lymphoma of b-cell origin, the tumor cells of which have lost the expression of main b-cell antigens. The standard immunophenotype of the tumor substrate, according to immunohistochemical studies, is characterized by the expression of such markers as CD15, CD30 and PAX-5, while tumor cells have a negative expression of CD3, CD19 and in most cases also CD20 and CD45 (or express this antigen rather weakly). The knowledge gained in recent years has increased the effectiveness of diagnosis, prognosis and treatment of LH. Flow cytometry, as a method of immunophenotyping in classical LH, was practically not used due to the difficulty of distinguishing single reed–sternberg–berezovsky tumor cells (RSB) and the tumor microenvironment (reactive background), which is very rich in cellular elements and is represented by T cells, B cells, eosinophils, histiocytes and plasma cells. However, in the recent past, several studies have successfully attempted to identify rsb cells using multiparameter flow cytometry during aspiration with a thin needle or biopsy of lymph node tissue to confirm or supplement immunohistochemical staining during primary diagnosis. Taking into account the very characteristic immunophenotype of RSB cells, the flow cytometry may become an additional diagnostic method of classical LH in the future. In this review, we summarize the data on the possibility of using the flow cytometry as an additional clinical diagnostic option in the primary diagnosis of classical LH.","PeriodicalId":37536,"journal":{"name":"Oncogematologiya","volume":"40 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135885561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Experience of 2&lt;sup&gt;nd&lt;/sup&gt; line therapy with eltrombopag in patients with immune thrombocytopenia","authors":"S. G. Zakharov, T. A. Mitina, R. V. Vardanyan, Z. R. Tekeeva, I. N. Kontievskiy, Yu. Yu. Chuksina, A. V. Zakharova","doi":"10.17650/1818-8346-2023-18-3-65-69","DOIUrl":"https://doi.org/10.17650/1818-8346-2023-18-3-65-69","url":null,"abstract":"Background. Immune thrombocytopenia (ITP), or idiopathic thrombocytopenic purpura, is a hematological autoimmune disease characterized by bleeding and an isolated decrease in platelet count <100 × 10 9 / l. The decision to start treatment for ITP depends on several factors. The ITP treatment strategy is based on the clinical symptoms, with a focus on reducing the risk of severe bleeding and increasing platelet counts. Aim. To evaluate the efficacy of 2 nd line therapy with the thrombopoietin receptor agonist eltrombopag in patients with ITP. Materials and methods. 490 patients with ITP are under observation at the center for orphan diseases of M. F. Vladimirskiy Moscow Regional Research Clinical Institute. The present study included 186 patients with primary ITP after 1 st line glucocorticosteroid therapy. eltrombopag, a thrombopoietin receptor agonist, was prescribed as the 2 nd line of therapy. Results. The median platelet count prior to eltrombopag therapy in all patients was 27.5 × 10 9 / l. after eltrombopag therapy, a significant (by 490 %) increase in platelet levels (median 135 × 10 9 / l) and a complete response according to clinical recommendations were noted. Conclusion. Glucocorticosteroids (prednisolone, dexamethasone) remain the drugs of choice for the 1 st line of therapy. Treatment with drugs of this group in most cases allows achieving an optimal platelet level and preventing bleeding. In case of inefficiency, intolerance, occurrence of side effects, the appointment of thrombopoietin receptor agonists eltrombopag or romiplostim is recommended. therapy with eltrombopag at a dose of 50 mg daily for several weeks has been able to achieve an increase in platelet levels, correct hemorrhagic syndrome, reduce the number of side effects during first-line glucocorticosteroid therapy, and improve the patient’s quality of life.","PeriodicalId":37536,"journal":{"name":"Oncogematologiya","volume":"63 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135885716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Follicular lymphoma in children and adolescents: clinical, diagnostic and therapeutic features","authors":"T. T. Valiev, A. S. Volkova, M. A. Postoykina, D. S. Abramov, A. R. Karibova, A. A. Odzharova, Yu. E. Ryabukhina, P. A. Zeynalova","doi":"10.17650/1818-8346-2023-18-3-18-25","DOIUrl":"https://doi.org/10.17650/1818-8346-2023-18-3-18-25","url":null,"abstract":"Ffollicular lymphoma (FL) is one of the most common non-Hodgkin’s lymphomas in adults, while it is a diagnosis of exclusion in adolescents and children. Clinical manifestations of FL in children are represented by long-term asymptomatic lymphadenopathy, less commonly by extranodal areas involvement. treatment standards for FL in children have not been developed and may vary from observational tactics (with the radical resection of a single focus during a biopsy) to the use of radiation therapy and polychemotherapy. Pediatric type follicular lymphoma was first identified as a distinct variant in 2008 in the world Health organization classification of hematopoietic and lymphoid tissue tumors. Clinical, morphological (cytological type 3A), Immunohistochemical (absence of bcl2 expression in the center of the follicle) and cytogenetic (absence of t(14;18)(q32;q21)) features served as the reason for separation into an independent nosological variant. Despite the term “pediatric”, cases of pediatric type FL have been described in adults over 30 years of age. Most often, the disease is diagnosed in the early stages (I, II) and is characterized by a favorable prognosis. In children and adolescents, FL occurs not only of the pediatric type. we present a clinical case of a typical “adult” type FL (grade 1–2) in a 17-year-old patient. the cHop therapy (cyclophosphamide, doxorubicin, vincristine, and prednisolone) with rituximab resulted in a complete remission, which lasted more than 2.5 years.","PeriodicalId":37536,"journal":{"name":"Oncogematologiya","volume":"11 Suppl 4 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136024281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune thrombocytopenia in the aspect of multiple primary neoplasms","authors":"R. V. Vardanyan, S. G. Zakharov, T. A. Mitina, P. A. Zeynalova, Yu. Yu. Chuksina, A. V. Zakharova","doi":"10.17650/1818-8346-2023-18-3-44-49","DOIUrl":"https://doi.org/10.17650/1818-8346-2023-18-3-44-49","url":null,"abstract":"Multiple primary malignant neoplasms (MPMNs) is a complex process in which the development of 2 or more neoplasms simultaneously or after a certain interval is observed. MPMNs develop independently from each other within one or more organs. Many etiopathogenetic factors can cause MPMNs. Numerous studies have been conducted to study the effect of T-cell immunity on the development of this pathology. Today, there is a steady upward trend in the prevalence of mpmns, which, on the one hand, is due to more effective methods of early diagnosis, an increase in patient overall survival, and early antitumor therapy (chemotherapy, radiation therapy), on the other hand, this trend may be associated with pathology of T-regulatory cellular immunity. T-regulatory cells play a strategic role in the development of immune homeostasis, and their function is closely related to the occurrence of a wide range of pathologies, including autoimmune diseases and malignant neoplasms. The article presents a clinical case of a patient with a confirmed diagnosis: mpmn, immune thrombocytopenia (idiopathic thrombocytopenic purpura). On prednisolone therapy, remission was achieved for 2 metachronous tumors and a complete hematological response for immune thrombocytopenia was obtained. there were no signs of hemorrhagic syndrome and complications during prednisone therapy. It is planned to continue monitoring the patient for metachronous tumors by a hematologist, an oncologist at the place of residence, as well as at the center for orphan diseases of the Moscow Regional Research Clinical Institute named after M. F. Vladimirsky with control of platelets and general condition.","PeriodicalId":37536,"journal":{"name":"Oncogematologiya","volume":"19 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136024280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of locally produced anti-CD19 CAR-T cells in the treatment of relapsed/refractory B-cell lymphomas in adults","authors":"N. E. Konoplya, O. A. Kalenik, I. N. Severin, A. A. Savritskaya, N. M. Bobrova, T. M. Doroshenko, A. S. Portyanko","doi":"10.17650/1818-8346-2023-18-3-26-34","DOIUrl":"https://doi.org/10.17650/1818-8346-2023-18-3-26-34","url":null,"abstract":"Background. Patients with B-cell lymphoma have an extremely unfavorable prognosis after relapse or in case of refractoriness to the first and consecutive lines of immunochemotherapy with the anti-CD19 CAR-T cells being the only therapeutic option to such patients. the manual preparation of anti-CD19 CAR-T lymphocytes was reproduced in the N. N. Alexandrov republican research and practical center for oncology and medical radiology (Minsk). Their safety was demonstrated. Aim. To estimate safety, tolerability and efficacy of the in-house CAR-T cells, including objective response rate, progression-free and overall survival. Materials and methods. The second generation anti-CD19 chimeric antigen receptor contained an anti-CD19 antibody scFv fragment, CD28 transmembrane domain, 4-1BB and CD3z signaling domains. the coding sequence was cloned into the lentiviral vector S4. The cell product was obtained by expansion of CD4- and CD8-positive lymphocytes populations with IL-7 and IL-15 after initial activation and lentiviral transduction with vector S4. CAR-T cells were infused into 8 patients with refractory forms of B-cell lymphoma after the preliminary lymphodepleting chemotherapy. Persistence of CAR-T cells was assessed by flow cytometry. therapeutic efficiency was assessed by positron emission tomography-computed tomography with 18 F-fluorodeoxyglucose. Results. Expansion of CAR-T cells with resulting b-cell aplasia was observed in all patients. the median of observation was 113 days (range 22–529 days). objective response rate was 100 %, complete remission was observed in 6 patients, partial response – in 1 patient. One patient died because of complications before the clinical response. Overall survival was 88 ± 12 %. cytokine release syndrome and neurotoxicity were not observed in 6 out of 8 patients despite a high tumor burden. Conclusion. Our study demonstrated efficiency and safety of the in-house CAR-T cells for the treatment of patients with refractory B-cell lymphomas.","PeriodicalId":37536,"journal":{"name":"Oncogematologiya","volume":"46 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136024273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An integrated treatment approach in patient with metastatic colorectal cancer and concomitant late cardiovascular complications of chemoradiotherapy for Hodgkin’s lymphoma. Clinical case","authors":"Yu. E. Ryabukhina, P. A. Zeynalova, A. A. Akhobekov, D. A. Chekini, E. K. Ibragimov, Z. M. Cheishvili, T. I. Kopaliani, V. E. Gruzdev, A. G. Zhukov, T. T. Valiev","doi":"10.17650/1818-8346-2023-18-3-35-43","DOIUrl":"https://doi.org/10.17650/1818-8346-2023-18-3-35-43","url":null,"abstract":"The high efficacy of the currently used combined chemoradiotherapy for Hodgkin’s lymphoma not only significantly increased overall survival, but also made it possible for most patients to achieve the same quality of life as in a healthy population. at the same time, the problem of identifying late treatment complications, in particular cardiovascular the high efficacy of the currently used combined chemoradiotherapy for Hodgkin’s lymphoma not only significantly increased overall survival, but also made it possible for most patients to achieve the same quality of life as in a healthy population. at the same time, the problem of identifying late treatment complications, in particular cardiovascular diseases, remains an urgent problem, the timely diagnosis of which is an important task. the development of a second malignant neoplasm and the appointment of drug antitumor therapy with cardiotoxic agents necessitate a multidisciplinary approach. In the presented clinical observation, such tactics of patient management made it possible not only to timely identify late cardiovascular complications of Hodgkin’s lymphoma chemoradiotherapy, but also to conduct treatment for the second malignant disease with cardiotoxic agents with a positive antitumor effect.","PeriodicalId":37536,"journal":{"name":"Oncogematologiya","volume":"30 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136024285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}